The association aims to elevate regional standards in the pharmaceutical, medical device, and cosmetic sectors. This recognition follows an on-site inspection by the Zhejiang Medical Products Administration in March 2026, where regulators evaluated the operational effectiveness of Jiuxin Medicine’s digital tracking infrastructure. The initiative requires scanning unique electronic identifiers at every stage, from manufacturer shipment to final dispensing at hospitals and pharmacies.
In section Releases
Ridgetech Subsidiary Secures Leadership Role in Zhejiang Biomedical Group
Zhejiang Jiuxin Medicine, a subsidiary of Ridgetech, Inc., has been appointed as a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association. The appointment, effective July 28, 2026, recognizes the company’s role in pioneering full-variety drug traceability scanning across Zhejiang Province.
Jiuxin Medicine functions as the offline B2B distribution pillar of Ridgetech’s dual-engine strategy, operating alongside the Allright online platform. By integrating AI and big-data analytics with the national drug traceability framework, the company seeks to identify distribution bottlenecks and enhance supply chain visibility. Frank Zhao, interim CEO and CFO of Ridgetech, noted that the appointment reinforces the company's commitment to regulatory compliance and the integration of emerging technologies to secure long-term growth. As of January 1, 2026, mandatory traceability data uploads have become a foundational requirement for designated healthcare providers under China’s national reform roadmap.
Comments (0)
No comments yet. Be the first!